

Improving uptake of cardiac rehabilitation with a smartphone enabled application and understanding barriers to success



AUTHORS: JT. RIVERS^{1,2,3}, C. SMITH¹, I. SMITH², J. CAMERON^{1,2} AFFILIATIONS: 1. Queensland Cardiovascular Group, Brisbane, Australia 2. St. Andrews War Memorial Hospital, Brisbane, Australia 3. St. Vincent's Private Hospital Northside, Brisbane, Australia

Background

Current guidelines recommend referral for cardiac rehabilitation following acute cardiac events but participation rates are poor.^{1,2} Uptake of cardiac rehabilitation (CR) remains a challenging problem for multiple reasons including: distance/transport, time, cultural, cost and psychological constraints.^{3,4}

This study evaluated the impact on CR participation associated with the introduction of a smartphone enabled app (CardihabTM) for patients declining conventional CR. Information on barriers to CR participation were collected.

Methods

204 consecutive patients were offered CR post angioplasty; 99 in phase one who were offered conventional CR only, and 105 in phase 2, initially offered conventional CR with app-based CR offered to those patients who declined conventional CR. Patients were followed throughout a 6-week CR program and participation rates were compared for Phase 1 and 2. Patients were evaluated based on the mode of CR in which they initially agreed to participate.

Patients declining all forms of CR in phase 2 were interviewed to assess reasons for non-participation.

The occurrence and cause of hospital readmissions within 12 months of the index cardiac event were retrospectively documented for Phase 2 patients.

Contact Information Dr John T Rivers Queensland Cardiovascular Group, Level 8, St Andrew's Specialist Centre, 457 Wickham Terrace, Brisbane QLD 4000 johnr@qcg.com.au

Results


- In Phase 1, 21 patients (21%) undertook conventional CR while in Phase 2, 43 patients (41%) elected to undertake conventional CR (p=0.002). Of the 62 patients declining conventional CR in Phase 2, a further 23 elected to participate in the app-based program. (Table 1)
- In Phase 2 a total of 66 patients (63%) undertook CR, using either the conventional or app-based program. The increase in CR participation from Phase 1 to Phase 2 was statistically significant (p<0.001). (Figure 1)</p>

Table 1: Summary of patient participation by mode of cardiac rehabilitation

	Phase 1 (n=99)		Phase 2 (n=105)		
	Male	Female	Male	Female	
Number Approached	73	26	79	26	p=0.806*
	(74%)	(26%)	(75%)	(25%)	
Median Age (IQR)	70	73	66	71	M: p=0.005*
	(63-74)	(68-80)	(58-71)	(62-77)	F: p=0.164*
Conventional CR Enrolled	21 (21%, CI:14%-30%)		43 (41%, CI:32%-51%)		p=0.002*
	13 (18%)	8 (31%)	31 (39%)	12 (46%)	
App-based CR Enrolled		10	23		
	n/a		21	2	
Total CR uptake	21 (21%, CI:14%-30%)		66 (63%, CI: 53%-71%)		p<0.001*
	13 (18%)	8 (31%)	52 (66%)	14 (54%)	

*p-values for comparison between phase 1 and phase 2. Cl, 95% Confidence intervals calculated using the Wilson score interval. IQR, interquartile range; CR, cardiac rehabilitation

Figure 1. Overall CR Participation Rates



- From Phase 1 to Phase 2, participation by males in the CR program increased from 18% to 66% (p<0.001). There was no significant difference for females (p=0.09). The increase in male participation arose from increased participation in the conventional program (18% to 39%), plus a significant contribution from those taking up the app-based program (21/48; 44%).
- Patients participating in the app-based CR were younger (median: 61 vs. 70 years, p=0.005)
- Patients who declined CR during Phase 2 (n=39) were interviewed to identify reasons for non-participation (Table 2). 9 patients (23%) reported psychosocial issues and 9 patients (23%) identified technology issues as reasons for not taking up appbased CR.

Table 2: Patient-reported reasons for declining participation in CR (n = 39)

Reason	Number (%)
Further cardiac procedure scheduled	11 (26%)
Psychosocial issues	9 (23%)
Technical concerns (device or operator) re app-based CR	9 (23%)
Comorbidities (Alzheimer's; hearing difficulties)	3 (0.08%)
Unable to be interviewed or living outside Australia	3 (0.08%)
Completed CR previously and feel another program won't be useful	2 (0.05%)

➡ Hospital readmissions (by primary diagnosis categories) within 12-months post the initial cardiac event for Phase 2 patients are shown in Table 3. Cardiac readmission was observed to be very low in the app-based (Cardihab) CR cohort at 4%, considerably higher at 33% for conventional CR patients and 13% for the no CR cohort (p=0.025). This may partly reflect a younger cohort in the app-based CR patients.

Note: Study not specifically designed to detect differences in readmission rates.

Table 3: Hospital readmissions within 12 months of index cardiac event

		No CR	Conventional CR	App-based CR
Patients (Phase 2)	n	39 (M: 69%)	43 (M: 70%)	23 (M: 91%)
	Age (IQR)	68 (61-74)	70 (63-74)	61 (56-69)
All readmissions	n	10 (M: 60%)	21 (M: 67%)	5 (M: 100%)
	Age (IQR)	65 (61-75)	69 (63-73)	68 (66-70)
	Proportion (%)	26% (15%-41%)	49% (35%-63%)	22% (10%-42%)
	n	5 (M: 60%)	13 (M: 77%)	1 (M: 100%)
Cardiac readmissions	Age (IQR)	66 (59-71)	69 (63-73)	68 (n/a)
	Proportion (%)	13% (6%-27%)	33% (19%-45%)	4% (1%-21%)

IQR, interquartile range; F2F, face to face. No IQR is provided where the number of cases is less than 5. Confidence intervals (95%) shown for proportions were calculated using the Wilson score interval.

Conclusions

- Providing the additional option of an appbased CR program to patients who declined conventional CR was associated with an increase in overall CR participation rate from 21% in phase 1 to 63% in phase 2.
- Use of a clinically validated, smart-phone enabled, digital CR program can improve CR participation and should be considered as a standard component of a CR service, particularly for patients who find conventional CR impractical, inconvenient or unappealing.
- Further trials are needed to assess the value of app-based risk factor modification on long term clinical outcomes.

Disclosures 1. I. Smith has not had an affiliation (financial or otherwise) with a commercial organization that may have a direct or indirect connection to the content of this presentation. **2.** J.T. Rivers and C. Smith work within Queensland Cardiovascular Group which is the clinical development partner for Cardihab Pty. Ltd. and a shareholder of Cardihab Pty. Ltd. JT. Rivers is a director of Cardihab Pty. Ltd. James Cameron (deceased) worked within Queensland Cardiovascular Group. (Financial interest: Modest <\$10K)

References 1. Chew DP, et al. National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. Heart Lung Circ. 2016;25(9):895-951. **2.** Institute. BHaD. No Second Chances: Controlling Risk in Cardiovascular Disease. In. Melbourne, Australia: Baker Heart and Diabetes Institute; 2018 **3.** Menezes AR, et al. Cardiac rehabilitation in the United States. Prog Cardiovasc Dis. 2014;56(5):522-529. **4.** Dalal HM, et al. Cardiac Rehabilitation. BMJ. 2015;351:h5000.